Cargando…

Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration

BACKGROUND: Vancomycin is frequently used in hemodialysis (HD) and in hemodiafiltration (HDF) patients and is usually administered in the last 30 or 60 minutes of a dialysis session. Vancomycin pharmacokinetics are not well described in HDF patients. The aim of this study is to develop a population...

Descripción completa

Detalles Bibliográficos
Autores principales: Westra, Niels, Proost, Johannes H., Franssen, Casper F. M., Wilms, Erik B., van Buren, Marjolijn, Touw, Daan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516654/
https://www.ncbi.nlm.nih.gov/pubmed/31086400
http://dx.doi.org/10.1371/journal.pone.0216801
_version_ 1783418225069916160
author Westra, Niels
Proost, Johannes H.
Franssen, Casper F. M.
Wilms, Erik B.
van Buren, Marjolijn
Touw, Daan J.
author_facet Westra, Niels
Proost, Johannes H.
Franssen, Casper F. M.
Wilms, Erik B.
van Buren, Marjolijn
Touw, Daan J.
author_sort Westra, Niels
collection PubMed
description BACKGROUND: Vancomycin is frequently used in hemodialysis (HD) and in hemodiafiltration (HDF) patients and is usually administered in the last 30 or 60 minutes of a dialysis session. Vancomycin pharmacokinetics are not well described in HDF patients. The aim of this study is to develop a population pharmacokinetic (PPK) model and dosing regimen for vancomycin in HDF patients and to evaluate its applicability in low-flux (LF-HD) patients. METHODS: Two-compartment PPK models were developed using data from HDF patients (n = 17), and was parameterized as follows: non-renal clearance (CLm), renal clearance as a fraction of creatinine clearance (fr), central volume of distribution (V1), intercompartmental clearance (CL12), peripheral volume of distribution (V2) and extracorporeal extraction ratio (Eec). We evaluated the final model in a cohort of LF-HD patients (n = 21). Dosing schemes were developed for a vancomycin 24-h AUC of 400 mg*h/L. RESULTS: Model parameters (± SD) were: CLm = 0.473 (0.271) L/h, fr = 0.1 (fixed value), V1 = 0.278 (0.092) L/kgLBMc, CL12 = 9.96 L/h (fixed value), V2 = 0.686 (0.335) L/kgLBMc and Eec = 0.212 (0.069). The model reliably predicted serum levels of vancomycin in both HDF and LF-HD patients during and between dialysis sessions. The median of the prediction error (MDPE) as a measure of bias is -0.7% (95% CI: -3.4%-1.7%) and the median of the absolute values of the prediction errors (MDAPE) as a measure of precision is 7.9% (95% CI: 6.0%-9.8%). In both HDF and LF-HD, the optimal vancomycin loading dose for a typical patient weighing 70 kg is 1700 mg when administered during the last 60 minutes of the hemodialysis session. Maintenance dose is 700 mg if administered during the last 30 or 60 minutes of the hemodialysis session. CONCLUSION: The developed PPK model for HDF is also capable of predicting serum levels of vancomycin in patients on LF-HD. A dosing regimen was developed for the use of vancomycin in HDF and LF-HD.
format Online
Article
Text
id pubmed-6516654
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65166542019-05-31 Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration Westra, Niels Proost, Johannes H. Franssen, Casper F. M. Wilms, Erik B. van Buren, Marjolijn Touw, Daan J. PLoS One Research Article BACKGROUND: Vancomycin is frequently used in hemodialysis (HD) and in hemodiafiltration (HDF) patients and is usually administered in the last 30 or 60 minutes of a dialysis session. Vancomycin pharmacokinetics are not well described in HDF patients. The aim of this study is to develop a population pharmacokinetic (PPK) model and dosing regimen for vancomycin in HDF patients and to evaluate its applicability in low-flux (LF-HD) patients. METHODS: Two-compartment PPK models were developed using data from HDF patients (n = 17), and was parameterized as follows: non-renal clearance (CLm), renal clearance as a fraction of creatinine clearance (fr), central volume of distribution (V1), intercompartmental clearance (CL12), peripheral volume of distribution (V2) and extracorporeal extraction ratio (Eec). We evaluated the final model in a cohort of LF-HD patients (n = 21). Dosing schemes were developed for a vancomycin 24-h AUC of 400 mg*h/L. RESULTS: Model parameters (± SD) were: CLm = 0.473 (0.271) L/h, fr = 0.1 (fixed value), V1 = 0.278 (0.092) L/kgLBMc, CL12 = 9.96 L/h (fixed value), V2 = 0.686 (0.335) L/kgLBMc and Eec = 0.212 (0.069). The model reliably predicted serum levels of vancomycin in both HDF and LF-HD patients during and between dialysis sessions. The median of the prediction error (MDPE) as a measure of bias is -0.7% (95% CI: -3.4%-1.7%) and the median of the absolute values of the prediction errors (MDAPE) as a measure of precision is 7.9% (95% CI: 6.0%-9.8%). In both HDF and LF-HD, the optimal vancomycin loading dose for a typical patient weighing 70 kg is 1700 mg when administered during the last 60 minutes of the hemodialysis session. Maintenance dose is 700 mg if administered during the last 30 or 60 minutes of the hemodialysis session. CONCLUSION: The developed PPK model for HDF is also capable of predicting serum levels of vancomycin in patients on LF-HD. A dosing regimen was developed for the use of vancomycin in HDF and LF-HD. Public Library of Science 2019-05-14 /pmc/articles/PMC6516654/ /pubmed/31086400 http://dx.doi.org/10.1371/journal.pone.0216801 Text en © 2019 Westra et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Westra, Niels
Proost, Johannes H.
Franssen, Casper F. M.
Wilms, Erik B.
van Buren, Marjolijn
Touw, Daan J.
Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title_full Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title_fullStr Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title_full_unstemmed Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title_short Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
title_sort vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516654/
https://www.ncbi.nlm.nih.gov/pubmed/31086400
http://dx.doi.org/10.1371/journal.pone.0216801
work_keys_str_mv AT westraniels vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration
AT proostjohannesh vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration
AT franssencasperfm vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration
AT wilmserikb vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration
AT vanburenmarjolijn vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration
AT touwdaanj vancomycinpharmacokineticmodeldevelopmentinpatientsonintermittentonlinehemodiafiltration